Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06007677 · ClinicalTrials.gov registry record · Phase 2
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
A Phase 2 study of Hereditary Angioedema, sponsored by Astria Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT06007677: Active Phase 2 study of Hereditary Angioedema, sponsored by Astria Therapeutics.
NCT06007677 is a Phase 2 study of Hereditary Angioedema that is active but no longer recruiting, run by Astria Therapeutics. The registered enrollment target is 56 participants, below the 72-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (22% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06007677, a Phase 2 study of Hereditary Angioedema, is active but no longer recruiting, sponsored by Astria Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
Conditions Studied
Interventions
- DRUG STAR-0215
Study Locations (20)
Other
- Diagnostic Consultative Center Convex Ltd. - Sofia
- Institute of Clinical Immunology/Allergology, Faculty Hospital, Hradec Kralove - Hradec Králové
- Charité Universitätsmedizin Berlin - Berlin
- Johann Wolfgang Goethe-Universität Frankfurt - Frankfurt
- Universitätsklinikum Ulm - Ulm
- Szpital Uniwersytecki w Krakowie - Krakow
California
- UC San Diego US HAEA Angioedema Center - San Diego
- Raffi Tachdjian MD, Inc - Santa Monica
- Allergy & Asthma Clinical Research - Walnut Creek
Alabama
- Allervie Clinical Research - Birmingham
Arizona
- Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD - Scottsdale
Arkansas
- Acuro Research - Little Rock
Maryland
- Institute for Asthma and Allergy, PC - Chevy Chase
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-09-26 |
| Est. Completion | 2031-03 |
| Phase | Phase 2 |
What the registry record for NCT06007677 still lists
NCT06007677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 72-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (22% lower).
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 1 intervention - of which STAR-0215 is the first listed.
NCT06007677 names 20 study sites across 13 states, led by Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06007677 about?
NCT06007677 is a clinical study titled "A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema". The goal of this trial is to enable the collection of information about long-term safety and clinical activity of STAR-0215 in participants with hereditary angioedema (HAE). Participants will receive repeat doses of STAR-0215 for up to 5 years.
What is the current status of trial NCT06007677?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2023-09-26. Estimated completion is 2031-03.
What conditions does trial NCT06007677 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT06007677?
The interventions under investigation include: STAR-0215 (DRUG).
Who is sponsoring clinical trial NCT06007677?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06007677 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06007677's enrollment target sits among peer trials
56 9th of 14 higher than 6 of 14 other Hereditary Angioedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hereditary Angioedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration
COMPLETED · Phase 2
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
RECRUITING · Phase 4
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI